Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Add-On Treatment in Genotype 1 or 4 Hcv Infected Patients Resistant to Pegylated Interferon-Alpha and Ribavirin

NCT01025297 is registered in ClinicalTrials.gov with Cytheris SA as lead sponsor.

NCT NCT01025297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01025297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Add-On Treatment in Genotype 1 or 4 Hcv Infected Patients Resistant to Pegylated Interferon-Alpha and Ribavirin
Lead sponsor
Cytheris SA
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2008
Completion date
March 31, 2013
Enrollment
18 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c